NCT06224218 Prostate Single Port & Laser Enucleation Comparison Trial
| NCT ID | NCT06224218 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois Chicago |
| Condition | Prostate Hyperplasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 116 participants |
| Start Date | 2024-01-15 |
| Primary Completion | 2027-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 116 participants in total. It began in 2024-01-15 with a primary completion date of 2027-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Surgical treatments for benign prostatic hyperplasia (BPH) are necessary when non-procedural approaches fail to alleviate lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO). Open simple prostatectomy and laser enucleation are recommended for prostatic adenoma size greater than 80 ml. Minimally invasive approaches, such as robotic-assisted simple prostatectomy, have gained popularity due to their comparable outcomes with lower morbidity. The introduction of the da Vinci single-port (SP) robotic platform offers potential advantages, but its outcomes have not been thoroughly investigated. This randomized controlled trial aims to compare the outcomes of SP simple prostatectomy performed using the da Vinci robotic platform versus thulium laser enucleation of the prostate for the treatment of BPH and BOO.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) who fail conservative treatment with drug therapy are eligible for surgical intervention. Exclusion Criteria: * Adults unable to consent Prisoners Cognitive impaired adults Coagulopathy
Contact & Investigator
Simone Crivellaro, MD
PRINCIPAL INVESTIGATOR
University of Illinois at Chicago, Department of Urology
Frequently Asked Questions
Who can join the NCT06224218 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 88 Years, studying Prostate Hyperplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06224218 currently recruiting?
Yes, NCT06224218 is actively recruiting participants. Contact the research team at rsauer1@uic.edu for enrollment information.
Where is the NCT06224218 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06224218 clinical trial?
NCT06224218 is sponsored by University of Illinois Chicago. The principal investigator is Simone Crivellaro, MD at University of Illinois at Chicago, Department of Urology. The trial plans to enroll 116 participants.